



US008821473B2

(12) **United States Patent**
Michal et al.

(10) **Patent No.:** **US 8,821,473 B2**
(45) **Date of Patent:** **Sep. 2, 2014**

(54) **METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS**

(75) Inventors: **Eugene T. Michal**, San Francisco, CA (US); **Evgenia Mandrusov**, Campbell, CA (US); **Charles D. Claude**, Santa Clara, CA (US); **Ni Ding**, San Jose, CA (US); **Murthy Simhambhatla**, San Jose, CA (US); **Syed Faiyaz Ahmed Hossainy**, Fremont, CA (US); **Srinivasan Sridharan**, Morgan Hill, CA (US); **Paul Consigny**, San Jose, CA (US)

(73) Assignee: **Abbott Cardiovascular Systems Inc.**, Santa Clara, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 406 days.

(21) Appl. No.: **12/632,612**

(22) Filed: **Dec. 7, 2009**

(65) **Prior Publication Data**

US 2010/0144635 A1 Jun. 10, 2010

Related U.S. Application Data

(62) Division of application No. 10/414,767, filed on Apr. 15, 2003, now Pat. No. 7,641,643.

(51) **Int. Cl.**

A61M 31/00 (2006.01)
A61K 31/7088 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/0019** (2013.01); **A61K 31/7088** (2013.01); **A61K 9/0024** (2013.01)
USPC **604/500**; **604/508**; **604/509**

(58) **Field of Classification Search**

USPC **604/500**, **508**, **509**, **96.01**, **890.1**; **514/56**, **57**; **623/1**, **11**, **12**; **600/1-8**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,512,569 A 6/1950 Saffir
3,144,868 A 8/1964 Jascalevich
(Continued)

FOREIGN PATENT DOCUMENTS

EP 0331584 9/1989
EP 0861632 9/1998
(Continued)

OTHER PUBLICATIONS

Abbott Cardiovascular Systems, Final Office Action mailed Apr. 15, 2011 for U.S. Appl. No. 10/414,602.

(Continued)

Primary Examiner — Manuel Mendez

(74) *Attorney, Agent, or Firm* — Randy Shen; Blakely Sokoloff Taylor & Zafman LLP

(57) **ABSTRACT**

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structurally reinforcing agents. In other embodiments, agents are introduced into a ventricle to increase compliance of the ventricle. In an alternative embodiment, the prevention of remodeling includes the prevention of thinning of the ventricular infarct zone. In another embodiment, the prevention of remodeling and thinning of the infarct zone involves the cross-linking of collagen and prevention of collagen slipping. In other embodiments, the structurally reinforcing agent may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

24 Claims, 35 Drawing Sheets

